🟢 Femasys is trading 5% up today after FDA approved modular PMA pathway for FemBloc

Femasys is trading 5% up now at $2.87 after the FDA approved a modular PMA pathway for investigational FemBloc, its non-surgical permanent birth-control technology.

• The pathway allows FDA review of completed application sections before final clinical data.
• It advances the U.S. regulatory process without granting marketing approval.
• Shares remain volatile after the August 19 surge, with investors taking profits premarket before the August 21 rebound.